Pulmonary Edema

Article Author:
Ryan Malek
Article Editor:
Shadi Soufi
Updated:
4/29/2020 2:44:26 PM
PubMed Link:
Pulmonary Edema

Introduction

Pulmonary edema can be defined as an abnormal accumulation of extravascular fluid in the lung parenchyma. This process leads to diminished gas exchange at the alveolar level, progressing to potentially causing respiratory failure. Its etiology is either due to a cardiogenic process with the inability to remove sufficient blood away from the pulmonary circulation or non-cardiogenic precipitated by injury to the lung parenchyma. It is an important pathologic feature in many disease processes, and hence learning the underlying disease process is crucial to guide its management. Clinical features include progressive worsening dyspnea, rales on lung auscultation, and worsening hypoxia.[1]

Etiology

Pulmonary edema can be broadly classified into cardiogenic and noncardiogenic pulmonary edema.

Cardiogenic or volume-overload pulmonary edema arises due to a rapid elevation in the hydrostatic pressure of the pulmonary capillaries. This is typically seen in disorders involving left ventricular systolic and diastolic function (acute myocarditis including other etiologies of non-ischemic cardiomyopathy, acute myocardial infarction), valvular function (aortic/mitral regurgitation and stenosis in the moderate to the severe range), rhythm (atrial fibrillation with a rapid ventricular response, ventricular tachycardia, high degree, and third-degree heart block).[2]

Noncardiogenic pulmonary edema is caused by lung injury with a resultant increase in pulmonary vascular permeability leading to the movement of fluid, rich in proteins, to the alveolar and interstitial compartments. Acute lung injury with severe hypoxemia is referred to as acute respiratory distress syndrome (ARDS) and is seen in various conditions directly affecting the lungs, such as pneumonia, inhalational injury, or indirectly, such as sepsis, acute pancreatitis, severe trauma with shock, multiple blood transfusions.[3]

Epidemiology

More than 1 million patients are admitted each year with a diagnosis of pulmonary edema secondary to cardiac causes (heart failure).[4] An estimated 190,000 patients are diagnosed with acute lung injury each year.[5] About 1.5 to 3.5 cases/100,000 population are diagnosed with ARDS.

Pathophysiology

The resultant pathology of increased extravascular fluid content in the lung remains common to all forms of pulmonary edema. However, the underlying mechanism leading to the edema arises from the disruption of various complex physiologic processes, maintaining a delicate balance of filtration of fluid and solute across the pulmonary capillary membrane. This imbalance can be from one or more of the following factors:

  • Increase in intravascular hydrostatic pressure transmitted in a retrograde fashion to the pulmonary microvasculature
  • Increase in interstitial hydrostatic pressure
  • Endothelial injury and disruption of epithelial barriers
  • Decrease in oncotic pressure due to underlying hepatic, renal, malnutrition, and other protein-losing states. 
  • Lymphatic insufficiency
  • Increased negative interstitial pressure 

The relationship between hydrostatic and oncotic forces in relation to net fluid filtration is best explained by Ernest Starling’s equation. The rate of fluid filtration is determined by the differences in the hydrostatic and oncotic pressures between the pulmonary capillaries and interstitial space.[1][3][6]

History and Physical

Progressively worsening dyspnea, tachypnea, and rales (or crackles) on examination with associated hypoxia are the clinical features common to both cardiogenic and noncardiogenic pulmonary edema.

Cough with pink frothy sputum noted due to hypoxemia from alveolar flooding and auscultation of an S3 gallop could suggest cardiogenic edema. Similarly, the presence of murmurs, elevated jugular venous pressure, peripheral edema may point towards a cardiac etiology.

In patients with non-cardiogenic pulmonary edema, the symptoms of infections such as fever, cough with expectoration, dyspnea pointing to likely pneumonia, recent trauma, blood transfusions, should be carefully assessed as these patients may progress to acute respiratory distress syndrome.  

Auscultation remains the mainstay of bedside assessment in all patients with respiratory symptoms. More specifically, hearing of either fine or coarse crackles is very crucial to determine the next steps in the management. Fine crackles are heard in cardiogenic pulmonary edema. They exclusively heard in the inspiratory phase when the small airways, which were shut during expiration, open abruptly.[7]

Evaluation

In addition to a thorough history and physical examination, electrocardiogram assists in diagnosing cardiac ischemia or myocardial infarction. It is a quick, inexpensive, and relatively less specialized test that can be done at the bedside.

Following are a variety of diagnostic tools utilized to help diagnose pulmonary edema and, more importantly, differentiate between its different types. 

Laboratory Testing

Brain-type natriuretic peptide (BNP) is secreted by the cardiac myocytes of the left ventricles in response to stretching caused by increased ventricular blood volume or increased intracardiac pressures. Elevated BNP levels correlate with left ventricular end-diastolic pressure as well as pulmonary occlusion pressure and can be seen in patients with congestive heart failure.[3] BNP levels <100 pg/ml suggests heart failure is less likely, and levels greater than 500 pg/ml suggest a high likelihood of heart failure. Levels between 100 and 500 pg/ml do not help in the diagnosis of heart failure and are often seen in critically ill patients.[3] 

Troponin elevation is commonly noted in patients with damage to myocytes, such as acute coronary syndrome. They, however, are also noted to be elevated in patients with severe sepsis.[3]

Hypoalbuminemia (≤3.4 g/dL) is an independent marker of increased in-hospital and post-discharge mortality for patients presenting in acute decompensated heart failure.[8] Low albumin in isolation does not lead to pulmonary edema as there is a concurrent drop in pulmonary interstitial and plasma albumin levels preventing the creation of a transpulmonary oncotic pressure gradient.[9] 

Obtaining serum electrolyte levels, including renal function, serum osmolarity, toxicology screening, help in patients with pulmonary edema due to toxic ingestion. Obtaining lipase and amylase levels help diagnose acute pancreatitis.  

Radiographic Testing

Both posteroanterior and lateral views in standard imaging or anteroposterior views in portable imaging are utilized. Cardiogenic pulmonary edema is characterized by the presence of central edema, pleural effusions, Kerley B septal lines, peribronchial cuffing, and enlarged heart size. In noncardiogenic etiologies, the edema pattern is typically patchy and peripheral that can demonstrate the presence of ground-glass opacities and consolidations with air bronchograms.[10] Pleural effusions are more commonly seen in the cardiogenic type.[1]

Echocardiography 

Assists in the diagnosis of left ventricular systolic dysfunction and valvular dysfunction. Through modalities, including tissue Doppler imaging of the mitral annulus, the presence and degree of diastolic dysfunction can be assessed.[3]

Lung Ultrasound

A newer technique that is noninvasive and does not involve radiation exposure. It is most commonly used in intensive care units, emergency rooms, and operating rooms. It helps detect the accumulation of extravascular lung water (EVLW) ahead of the clinical manifestations.[10]

Pulmonary Artery Catheterization

Often considered a gold standard in the determination of the etiology of pulmonary edema, it is an invasive test that helps monitor systemic vascular resistance, cardiac output, and filling pressures. An elevated pulmonary artery occlusion pressure over 18 mm Hg is helpful in the determination of cardiogenic pulmonary edema.[3]

Transpulmonary Thermodilution

It is an invasive testing modality that is performed in patients typically undergoing major cardiac, vascular, or thoracic surgeries. They are also used in septic shock and monitors several hemodynamic indices such as cardiac index, mixed venous oxygen saturation, stroke volume index, and EVLW.[10]

Treatment / Management

Therapeutic goals in patients with pulmonary edema include alleviation of symptoms and treatment of the underlying pathologic condition.

Diuretics remain the mainstay of treatment, and furosemide being the most commonly used medication. Higher doses are associated with more improvement in dyspnea, however, also associated with transient worsening of renal function.[11]

Vasodilators can be added as an adjuvant therapy to the diuretics in the management of pulmonary edema.[12] IV nitroglycerin (NTG) is the drug of choice, and it lowers preload and pulmonary congestion. NTG should only be used when the systolic blood pressure (SBP) is > 110 mm Hg. Nesiritide is a recombinant brain natriuretic peptide which has vasodilatory properties. It has been shown to reduce pulmonary capillary wedge pressure (PCWP) and filling pressures significantly, but no subsequent improvement in dyspnea has been noted.[13] Newer drugs like serelaxin, a recombinant human form of relaxin, induced nitric oxide activation, which causes vasodilation. Clevidipine is an ultra-short-acting calcium channel blocker, initiated very early in the presentation, has been associated with reduced length of stay, improved dyspnea, and less frequent ICU admission.[14] 

Nifedipine has been utilized in the prophylaxis and treatment of high altitude pulmonary edema (HAPE). This calcium channel blocker counteracts the hypoxia-mediated vasoconstriction of the pulmonary vasculature. This leads to the lowering of the pulmonary arterial pressure with subsequent improvements in gas exchange, exercise capability, and chest radiography.[15] Nifedipine is only used as a prophylactic strategy when altitude acclimatization cannot be achieved in high-risk individuals and situations (rapid rate of ascent, extreme physical exertion, recent respiratory tract infection, and low altitude of native place of residence).[16]

Inotropes, such as dobutamine and dopamine, are used in the management of pulmonary congestion when associated with low SBP and signs of tissue hypoperfusion. Significant adverse events include tachyarrhythmias, ischemia, and hypotension. Milrinone is an IV inotrope with vasodilatory properties but associated with an increase in post-discharge mortality.[17]

Morphine reduces systemic vascular resistance and acts as an analgesic and anxiolytic. It has been used in the management of pulmonary edema secondary to acute coronary syndrome. However, it may cause respiratory depression needing intubation and generally not recommended.[11]

Ventilatory support, both noninvasive and invasive, is used to improve oxygenation, direct alveolar, and interstitial fluids back into the capillaries, improve hypercarbia and hence reverse respiratory acidosis, and lastly, tissue oxygenation. It also aims at reducing the work of breathing. The decision to provide ventilatory support is based on clinical improvement with a trial of the above-mentioned drugs, patient's mental status, overall energy, or lack of such. In patients on invasive mechanical ventilation, continuous monitoring of hemodynamics is essential as a reduction in preload can lead to reduced cardiac output and thus a fall in SBP. Noninvasive mechanical ventilation, when initiated early in the management of pulmonary edema, has been associated with lower occurrences of respiratory muscle fatigue and, thus, reduction in invasive ventilation.[11]

Differential Diagnosis

Immersion pulmonary edema from drowning, neurogenic pulmonary edema from stroke, head trauma, medication hypersensitivities or toxic ingestions, blood transfusions leading to transfusion-related acute lung injury (TRALI), liver disease, pulmonary embolism or infarct, and uremia.[18]

Prognosis

Pulmonary edema is an acutely decompensated state due to either cardiac or noncardiac etiologies. Temporizing measures such as supplemental oxygenation, diuretics, nitrates, and morphine help manage dyspnea, hypoxemia. However, definitive management of the underlying causes is necessary to prevent its recurrences. Prognostic predictions are overall difficult to quantify, given the vast number of cardiogenic and non-cardiogenic etiologies of pulmonary edema and their individual mortality data. Pulmonary edema's advanced state of ARDS has had progressively improved outcomes. Hospital mortality has decreased from 60% from 1967 through 1981 to the range of 30% to 40% in the 1990s.[19] Furthermore, analysis ARDS mortality studies demonstrated a decline in overall mortality of about 1.1% per year from 1994 to 2006. Prognosis utilizing mortality data is largely variable and depends on the precipitating process of ARDS.[20] 

Complications

Since pulmonary edema is a result of complex physiologic derangements, be it cardiac, hepatic, multiorgan system involvement, toxic stimuli, the complications arising from it are generally secondary to the aforementioned pathophysiologic processes. Cardiogenic pulmonary edema can progress to respiratory failure requiring the utilization of a mechanical ventilator. ARDS is a complication of acute lung injury with progressive hypoxemia, also requiring intubation and mechanical ventilation.

Deterrence and Patient Education

Patients with a history of ischemic or valvular cardiac disease must be educated on the symptoms of pulmonary edema on every clinic visit with their doctors. Counseling on a low salt diet, regular exercise, and medication compliance must be emphasized.

Enhancing Healthcare Team Outcomes

Pulmonary edema can be a result of a multi-organ involvement, and hence the involvement of specialty teams such as internists, cardiology, pulmonology early in the course is recommended for timely initiation of targeted therapy to improve patient outcomes. Education to the nurses, medical students, nursing students, on the signs of respiratory failure, must be provided regularly for earlier identification of patients with an impending respiratory decompensation. Good history-taking skills must be practiced to identify factors such are medication non-compliance, a poor socioeconomic situation, illicit drug use to avoid recurrences or readmissions.


References

[1] Murray JF, Pulmonary edema: pathophysiology and diagnosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2011 Feb;     [PubMed PMID: 21219673]
[2] Ghofrani HA, [Pulmonary edema]. Der Internist. 2004 May;     [PubMed PMID: 15052405]
[3] Ware LB,Matthay MA, Clinical practice. Acute pulmonary edema. The New England journal of medicine. 2005 Dec 29;     [PubMed PMID: 16382065]
[4] Go AS,Mozaffarian D,Roger VL,Benjamin EJ,Berry JD,Borden WB,Bravata DM,Dai S,Ford ES,Fox CS,Franco S,Fullerton HJ,Gillespie C,Hailpern SM,Heit JA,Howard VJ,Huffman MD,Kissela BM,Kittner SJ,Lackland DT,Lichtman JH,Lisabeth LD,Magid D,Marcus GM,Marelli A,Matchar DB,McGuire DK,Mohler ER,Moy CS,Mussolino ME,Nichol G,Paynter NP,Schreiner PJ,Sorlie PD,Stein J,Turan TN,Virani SS,Wong ND,Woo D,Turner MB, Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation. 2013 Jan 1;     [PubMed PMID: 23239837]
[5] Rubenfeld GD,Caldwell E,Peabody E,Weaver J,Martin DP,Neff M,Stern EJ,Hudson LD, Incidence and outcomes of acute lung injury. The New England journal of medicine. 2005 Oct 20;     [PubMed PMID: 16236739]
[6] Sibbald WJ,Anderson RR,Holliday RL, Pathogenesis of pulmonary edema associated with the adult respiratory distress syndrome. Canadian Medical Association journal. 1979 Feb 17;     [PubMed PMID: 376080]
[7] Sarkar M,Madabhavi I,Niranjan N,Dogra M, Auscultation of the respiratory system. Annals of thoracic medicine. 2015 Jul-Sep;     [PubMed PMID: 26229557]
[8] Bonilla-Palomas JL,Gámez-López AL,Moreno-Conde M,López-Ibáñez MC,Anguita-Sánchez M,Gallego de la Sacristana A,García-Catalán F,Villar-Ráez A, Hypoalbuminemia in acute heart failure patients: causes and its impact on hospital and long-term mortality. Journal of cardiac failure. 2014 May;     [PubMed PMID: 24486927]
[9] Taylor AE, Capillary fluid filtration. Starling forces and lymph flow. Circulation research. 1981 Sep;     [PubMed PMID: 7020975]
[10] Assaad S,Kratzert WB,Shelley B,Friedman MB,Perrino A Jr, Assessment of Pulmonary Edema: Principles and Practice. Journal of cardiothoracic and vascular anesthesia. 2018 Apr;     [PubMed PMID: 29174750]
[11] Chioncel O,Collins SP,Ambrosy AP,Gheorghiade M,Filippatos G, Pulmonary Oedema-Therapeutic Targets. Cardiac failure review. 2015 Apr;     [PubMed PMID: 28785430]
[12] McMurray JJ,Adamopoulos S,Anker SD,Auricchio A,Böhm M,Dickstein K,Falk V,Filippatos G,Fonseca C,Gomez-Sanchez MA,Jaarsma T,Køber L,Lip GY,Maggioni AP,Parkhomenko A,Pieske BM,Popescu BA,Rønnevik PK,Rutten FH,Schwitter J,Seferovic P,Stepinska J,Trindade PT,Voors AA,Zannad F,Zeiher A,Bax JJ,Baumgartner H,Ceconi C,Dean V,Deaton C,Fagard R,Funck-Brentano C,Hasdai D,Hoes A,Kirchhof P,Knuuti J,Kolh P,McDonagh T,Moulin C,Popescu BA,Reiner Z,Sechtem U,Sirnes PA,Tendera M,Torbicki A,Vahanian A,Windecker S,McDonagh T,Sechtem U,Bonet LA,Avraamides P,Ben Lamin HA,Brignole M,Coca A,Cowburn P,Dargie H,Elliott P,Flachskampf FA,Guida GF,Hardman S,Iung B,Merkely B,Mueller C,Nanas JN,Nielsen OW,Orn S,Parissis JT,Ponikowski P, ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European journal of heart failure. 2012 Aug;     [PubMed PMID: 22828712]
[13] Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002 Mar 27;     [PubMed PMID: 11911755]
[14] Peacock WF,Chandra A,Char D,Collins S,Der Sahakian G,Ding L,Dunbar L,Fermann G,Fonarow GC,Garrison N,Hu MY,Jourdain P,Laribi S,Levy P,Möckel M,Mueller C,Ray P,Singer A,Ventura H,Weiss M,Mebazaa A, Clevidipine in acute heart failure: Results of the A Study of Blood Pressure Control in Acute Heart Failure-A Pilot Study (PRONTO). American heart journal. 2014 Apr;     [PubMed PMID: 24655702]
[15] Bärtsch P,Maggiorini M,Ritter M,Noti C,Vock P,Oelz O, Prevention of high-altitude pulmonary edema by nifedipine. The New England journal of medicine. 1991 Oct 31;     [PubMed PMID: 1922223]
[16] Rashid H,Hashmi SN,Hussain T, Risk factors in high altitude pulmonary oedema. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP. 2005 Feb;     [PubMed PMID: 15730835]
[17] Cuffe MS,Califf RM,Adams KF Jr,Benza R,Bourge R,Colucci WS,Massie BM,O'Connor CM,Pina I,Quigg R,Silver MA,Gheorghiade M, Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002 Mar 27;     [PubMed PMID: 11911756]
[18] Phillips JF,Neiman HL,Reeder MM, Noncardiac causes of pulmonary edema. JAMA. 1975 Nov 3;     [PubMed PMID: 1242179]
[19] Milberg JA,Davis DR,Steinberg KP,Hudson LD, Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993. JAMA. 1995 Jan 25;     [PubMed PMID: 7815658]
[20] Zambon M,Vincent JL, Mortality rates for patients with acute lung injury/ARDS have decreased over time. Chest. 2008 May;     [PubMed PMID: 18263687]